Study Evaluating Pneumococcal Meningitis in the Paediatric Population in Spain Four Years After the Marketing of Prevenar.
This study has been completed.
Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Information provided by:
Wyeth is now a wholly owned subsidiary of Pfizer
ClinicalTrials.gov Identifier:
NCT00227214
First received: September 12, 2005
Last updated: June 24, 2010
Last verified: June 2010
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The aim of this study is to determine the prevalence of pneumococcal meningitis in the paediatric population in Spain four years after the marketing of Prevenar. Also secondary objectives are: 1) to determine the clinical characteristics and outcome of the disease; and 2) to determine serotypes and antibiotic resistance patterns.
| Condition |
|---|
|
Pneumococcal Meningitis |
| Study Type: | Observational |
| Study Design: | Time Perspective: Prospective |
| Official Title: | Prevalence of Pneumococcal Meningitis in the Paediatric Population in Spain Four Years After the Marketing of Prevenar. |
Resource links provided by NLM:
Further study details as provided by Wyeth is now a wholly owned subsidiary of Pfizer:
Eligibility| Ages Eligible for Study: | up to 14 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Study Population
Children from 0 up to 14 years of age with a diagnosis of confirmed or probable pneumococcal meningitis or with a diagnosis of suspected bacterial meningitis without bacterial or viral isolation.
Criteria
Inclusion Criteria:
- All children from 0 up to 14 years with diagnosis of confirmed or probable pneumococcal meningitis or with diagnosis of suspected bacterial meningitis without bacterial or viral isolation will be included into the study.
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00227214
Locations
| Spain | |
| Alcalá de Henares, Spain | |
| Alcorcón, Spain | |
| Badalona, Spain | |
| Barakaldo, Spain | |
| Barcelona, Spain | |
| Barco de Valdeorras, Spain | |
| Bilbao, Spain | |
| Boadilla del Monte, Spain | |
| CEE, Spain | |
| Esplugues de Llobregat, Spain | |
| Estella, Spain | |
| Ferrol, Spain | |
| Figueres, Spain | |
| Getafe, Spain | |
| Girona, Spain | |
| Granollers, Spain | |
| La Coruña, Spain | |
| Leganés, Spain | |
| Lleida, Spain | |
| Lugo, Spain | |
| Madrid, Spain | |
| Mondragón, Spain | |
| Monforte de Lemos, Spain | |
| Móstoles, Spain | |
| Ourense, Spain | |
| Pamplona, Spain | |
| Pontevedra, Spain | |
| Reus, Spain | |
| Ribeira, Spain | |
| Sabadell, Spain | |
| San Lorenzo de El Escorial, Spain | |
| San Sebastián, Spain | |
| Tarragona, Spain | |
| Terrasa, Spain | |
| Tudela, Spain | |
| Verín, Spain | |
| Vigo, Spain | |
| Vitoria, Spain | |
| Zumárraga, Spain | |
Sponsors and Collaborators
Wyeth is now a wholly owned subsidiary of Pfizer
Investigators
| Study Director: | Pfizer CT.gov Call Center | Wyeth is now a wholly owned subsidiary of Pfizer |
More Information
No publications provided
| ClinicalTrials.gov Identifier: | NCT00227214 History of Changes |
| Other Study ID Numbers: | 0887X-101539 |
| Study First Received: | September 12, 2005 |
| Last Updated: | June 24, 2010 |
| Health Authority: | Spain: Spanish Agency of Medicines |
Additional relevant MeSH terms:
|
Meningitis Meningitis, Pneumococcal Central Nervous System Infections Central Nervous System Diseases Nervous System Diseases Meningitis, Bacterial |
Central Nervous System Bacterial Infections Bacterial Infections Pneumococcal Infections Streptococcal Infections Gram-Positive Bacterial Infections |
ClinicalTrials.gov processed this record on May 16, 2013